Evidence map›Paper›PMID 27561800›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2016

[Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer 
with Brain Metastases].

Liyan Qu, Rui Geng, Xia Song

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. [Mechanisms and intervention strategies by which neuropsychological stress promotes central nervous system tumor recurrence through bloodZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Liyan QuDepartment of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
Rui GengDepartment of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
Xia SongDepartment of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases are frequently encountered in patients with non-small cell lung cancer (NSCLC) and are a significant cause of morbidity and mortality. Antiangiogenesis therapy plays a major role in the management of brain metastases in lung cancer. Bevacizumab have become the novel method for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the bevacizumab for NSCLC with brain metastases treatment. The key point is the efficacy and safety. In this review, bevacizumab therapy of NSCLC with brain metastases were summarized.

Indexed as

BevacizumabBrain NeoplasmsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeovascularization, PathologicSafetyBevacizumab

Identifiers

PMID27561800
PMCPMC5972979
OpenAlexW2522788573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.